Caribou Biosciences, Inc. - 8-K Filing
Caribou Biosciences reported first-quarter 2026 financial results with $2.4 million in licensing and third-party revenue, a 59% decrease in R&D expenses to $20.6 million, and $8.1 million in G&A expenses. The company had $118.6 million in cash and equivalents as of March 31, 2026, and expects these funds to last through 2027. It also announced alignment with the FDA on the pivotal ANTLER-3 trial design for vispa-cel in second-line large B cell lymphoma and RMAT designation for CB-011 in multiple myeloma. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CRBU